

June 7, 2023

**Notice concerning the Establishment of OPhrs Co., Ltd.**

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “ONO”) today announced that it resolved to establish OPhrs Co., Ltd. (OPhrs) as a wholly-owned subsidiary at the meeting of its Board of Directors held today.

**1. Purpose for establishment:**

In order to further promote our growth strategy, we have decided to establish a separate company having our own recruitment system and remuneration system to strategically and actively acquire highly specialized human resources such as digital human resources and innovation human resources.

In the future, we will be committed to actively recruit highly specialized human resources by aiming to advance and speed up recruitment methods and processes toward the achievement of the medium-term management plan.

**2. Outline of OPhrs Co., Ltd.:**

Name	OPhrs Co., Ltd.
Location	8-2, Kyutaromachi 1-chome Chuo-ku, Osaka
Representative	Mitsuhiro Takamiya
Establishment	July 3, 2023 (planned)
Capital	JPY 10 million
Staff	1 person (planned)
Business	Planning, investigation, research, training and consulting consignment related to each of the preceding items
Relationship	A wholly-owned subsidiary of ONO

**3. Future outlook**

An impact of this matter on the Company’s business results for the current fiscal year would be marginal. Should there be any events to be disclosed in the future, we will announce them in a timely manner.

**Contact:**

Ono Pharmaceutical Co., Ltd.

Corporate Communications

[public\\_relations@ono-pharma.com](mailto:public_relations@ono-pharma.com)